FDA Approves Entrectinib for Tumors with NTRK Fusions - NCI
PDF) Detecting NTRK , ROS1, and ALK gene fusions in gastrointestinal tumor patients.
Aiming for higher ambition: the Roche approach to cracking the code of cancer
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials - The Lancet Oncology
Entrectinib Is Effective Across NTRK Fusion Positive Solid Tumour Types
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials - The Lancet Oncology
Summary of Clinical Trial Results
Latest Rectal cancer Clinical Trials - Search and Apply Today
STARTRK2 Clinical Trial: A Basket Study of Entrectinib for the Treatment of Solid Tumors with Specific Gene Rearrangements
Tolerance profile and recommendation for use
Novel Entrectinib Trial Focuses on Gene Rearrangements Across Many Tumor Types
Pharmaceuticals | Free Full-Text | TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs | HTML
ALKA-372-001, STARTRK-1, and STARTRK-2 Trials
carcinoid clinical trials Archives - Carcinoid Cancer Foundation
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours
Are you searching for clinical trials? myTomorrows can help. In our latest video, we explain what a Treatment Search Report is and how myTomorrows... | By myTomorrows | Facebook
Healthcare Corporate Video Portfolio | DigiVid360
Entrectinib in NTRK Fusion-Positive Gastrointestinal Cancers: Integrated Analysis of Patients Enrolled in Three Trials (ALKA-37
Entrectinib, a new multi-target inhibitor for cancer therapy - ScienceDirect
EX-99.2
Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC - JTO Clinical and Research Reports
Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population | npj Precision Oncology
Frontiers | Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases
Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours - ESMO Open
